

Claim Amendments:

Claim 5 (allowed): An isolated TGF-beta fusion protein comprising amino acids 1 to 160 of SEQ ID NO: 8.

Claims 8-9 (withdrawn).

Claims 11-21 (withdrawn).

Claim 22 (amended): A TGF- $\beta$  RII fusion protein comprising: (1) a biologically active amino acid sequence which corresponds to all or all part of the extracellular region of native TGF- $\beta$  RII and which is at least ~~60~~ 90% homologous to SEQ ID NO: 9, or equivalents thereof, ~~or naturally occurring variants thereto~~; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- $\beta$ .

Claim 23 (previously presented): The fusion protein of claim 22, wherein the constant region comprises IgG.

Claim 24 (previously presented): The fusion protein of claim 23, wherein the constant region comprises IgG1.

Claim 25 (previously presented): The fusion protein of claim 24, wherein the constant region comprises the hinge C<sub>H</sub>2 or C<sub>H</sub>3 portion of IgG1.

Claim 26 (previously presented): The fusion protein of claim 22, wherein the biologically active amino acid sequence comprises amino acids 1 to 160 of SEQ ID NO: 9.

Claim 27 (previously presented): A TGF- $\beta$  RII fusion protein comprising: (1) a biologically active amino acid sequence which corresponds to all or part of the extracellular region of native TGF- $\beta$  RII and which is at least ~~60~~ 90% homologous to SEQ ID NO: 8, or equivalents thereof, ~~or naturally occurring variants thereto~~; and (2) a constant region of an immunoglobulin, wherein the fusion protein binds to TGF- $\beta$ .

Claim 28 (previously presented): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a fusion protein of claim 22.